The COVID-19 emergency and the mandatory social distancing have not stopped the initiatives of ASA and of its distributors who, thanks to the mixed “on site” and ‘on line” formula, continue to carry out meetings to analyse the company’s therapeutic solutions.
The most recent one was the “Taipei MLS® User Meeting” congress which took place at the Caesar Park in Taipei thanks to the cooperation of Gaia Genomics, our local partner.
The meeting was physically attended by 4 specialists in the field of physiotherapy and rehabilitation who shared their clinical experience in using the M6 and Mphi 75 devices and, remotely, by the contribution of Doctor Iliya Todorov, Director of the Educational Committee for the International Federation of Manual-Musculoskeletal Medicine and President of the Bulgarian Society of Manual-Musculoskeletal Medicine.
It fell to her to focus on the use of MLS® for treating lower limb pathologies by presenting many clinical cases.
Participants’ questions to Doctor Todorov in order to better understand the therapy’s value concentrated on three points:
“The interaction between the participants and the speaker was useful in order to answer questions in real-time, – Giacomo Granozio, ASA’s Export Area Manager explains – allowing an exchange of points of view and of experiences in the field”. The same opinion was held by Doctor Todorov who underlined how this meeting represented “a great opportunity to share knowledge and opinions with local physicians” and who hopes that “the cases presented will be useful for their daily practice”. Celine, Gaia Genomic’s CEO, is convinced of this: “The Professor’s speech had a great impact on the participants who, after her presentation, were convinced of the concrete benefits of MLS®”.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.